Episode Details
Back to Episodes
Cannabis Schedule III Rescheduling: Medical Market Boom and Adult-Use Uncertainty Ahead
Published 1 day, 9 hours ago
Description
In the past 48 hours, the cannabis industry has been electrified by a landmark federal rescheduling move. On April 22, 2026, Acting Attorney General Todd Blanche signed a DEA final order shifting FDA-approved marijuana drugs and state-licensed medical cannabis from Schedule I to Schedule III, eliminating Section 280E tax burdens for qualifying operators and prompting Treasury to explore retroactive relief[1][2][3]. A June 29 DEA hearing will debate adult-use inclusion[1].
Cannabis stocks surged on the news, fueled by hopes for better capital access and legitimacy, then pulled back as investors realized benefits favor medical operators over adult-use firms[2]. Q1 2026 U.S. sales hit 6.5 billion dollars, underscoring robust demand despite volatility[1].
Herbal Dispatch announced on April 27 it is scouting U.S. medical market entry via partnerships and joint ventures, leveraging its Canadian expertise in patient acquisition and veteran programs[4]. PharmaCann, however, laid off 132 in Colorado amid pressures[1].
State actions persist: Virginia set a launch date, Rhode Island's residency rule fell in court, while Ohio weakened its voter initiative[1]. Insurance premiums are climbing, with the global cannabis market at 2.4 billion dollars in 2025 premiums, projected to 7.2 billion by 2033[6].
Compared to prior weeks, this outpaces incremental Biden-era steps, marking Trump administration acceleration toward research and medical access[3][5][10]. No major consumer shifts or supply disruptions reported, but leaders like Herbal Dispatch are pivoting aggressively to capitalize. Broader reform looms, balancing excitement with regulatory risks[2][4].
(Word count: 248)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
Cannabis stocks surged on the news, fueled by hopes for better capital access and legitimacy, then pulled back as investors realized benefits favor medical operators over adult-use firms[2]. Q1 2026 U.S. sales hit 6.5 billion dollars, underscoring robust demand despite volatility[1].
Herbal Dispatch announced on April 27 it is scouting U.S. medical market entry via partnerships and joint ventures, leveraging its Canadian expertise in patient acquisition and veteran programs[4]. PharmaCann, however, laid off 132 in Colorado amid pressures[1].
State actions persist: Virginia set a launch date, Rhode Island's residency rule fell in court, while Ohio weakened its voter initiative[1]. Insurance premiums are climbing, with the global cannabis market at 2.4 billion dollars in 2025 premiums, projected to 7.2 billion by 2033[6].
Compared to prior weeks, this outpaces incremental Biden-era steps, marking Trump administration acceleration toward research and medical access[3][5][10]. No major consumer shifts or supply disruptions reported, but leaders like Herbal Dispatch are pivoting aggressively to capitalize. Broader reform looms, balancing excitement with regulatory risks[2][4].
(Word count: 248)
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI